Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase

Metabolism: Clinical and Experimental

Volumn 61, Issue 10, 2012, Pages 1452-1460

  Ohira, Masahiro ^a   Endo, Kei ^a   Saiki, Atsuhito ^a   Miyashita, Yoh ^a   Terai, Kensuke ^a   Murano, Takeyoshi ^a   Watanabe, Fusako ^a   Tatsuno, Ichiro ^a   Shirai, Kohji ^a  

^a TOHO UNIVERSITY SAKURA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE PHOSPHATE; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; MESSENGER RNA; MEVALONIC ACID; PITAVASTATIN; PRAVASTATIN; SIMVASTATIN;

ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; CELLS, CULTURED; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEIN LIPASE; MEVALONIC ACID; MUSCLE, SKELETAL; PYRROLES; QUINOLINES; RATS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84866742878     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2012.03.010     Document Type: Article

References (44)

1. The Simvastatin Pravastatin Study Group Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia Am J Cardiol 71 1993 1408 1414
2. D.R. Illingworth, and J.A. Tobert A review of clinical trials comparing HMG-CoA reductase inhibitors Clin Ther 16 1994 366 385 (Pubitemid 24321670)
3. Simvastatin Pravastatin European Study Group Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia Cardiology 85 1994 244 254
4. The Quality of Life Multicenter Group M.R. Weir, and M.L. Berger Comparison of the effects on quality of life and the efficacy and tolerability of lovastatin versus pravastatin Am J Cardiol 77 1996 475 479 (Pubitemid 26086635)
5. Y. Saito, N. Yamada, and T. Teramoto Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia: dose-finding study using the double-blind, three-group parallel comparison Arzneimittelforschung 52 2002 251 255 (Pubitemid 34438222)
6. The LIPID Study Group Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris Am J Cardiol 76 1995 474 479
7. R.W. Piepho The pharmacokinetics and pharmacodynamics of agents proven to raise high-density lipoprotein cholesterol Am J Cardiol 86 2000 35 40
8. C.M. Ballantyne, A.G. Olsson, and T.J. Cook Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S Circulation 104 2001 3046 3051 (Pubitemid 34014055)
9. T.J. Smilde, S. van Wissen, and H. Wollersheim Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolemia (ASAP): a prospective, randomized, double-blind trial Lancet 357 2001 577 581 (Pubitemid 32179609)
10. S. Leanne, J.P. Chris, S. James, C. Stuart, F. Ian for the WOSCOPS Group Factors affecting low-density lipoprotein and high-density lipoprotein cholesterol response to pravastatin in the West Of Scotland Coronary Prevention Study (WOSCOPS) Am J Cardiol 90 2002 731 736
11. P.A. Nilsson-Ehle, A.S. Garfinkel, and M.C. Shotz Lipolytic enzymes and plasma lipoprotein metabolism Annu Rev Biochem 49 1980 667 693
12. C.S. Louis, and J.P. Henry Lipoprotein lipase, lipases 1984 Elsevier Amsterdam 263 305
13. J.E.A. Braun, and D.L. Severson Regulation of the synthesis, processing and translocation of lipoprotein lipase Biochem J 287 1992 337 347
14. U. Sexena, M.G. Klein, and I.J. Goldberg Transport of lipoprotein lipase across endothelial cells Proc Natl Acad Sci U S A 88 1991 2254 2258 (Pubitemid 21916394)
15. B.V. Khan, T.V. Fungwe, and H.G. Wilcox Cholesterol is required for the secretion of very low density lipoprotein: in vivo studies Biochem Biophys Acta 1044 1990 297 304 (Pubitemid 20192404)
16. M. Huff, and J. Burnett 3-Hydroxyl-3-methylglutaryl coenzyme A reductase inhibitors and hepatic apolipoprotein B secretion Curr Opin Lipidol 8 1997 138 145 (Pubitemid 27290459)
17. G. Yoshino, T. Kazumi, and T. Kasama Effect of CS-514 (pravastatin) on VLDL kinetics in rats Atherosclerosis 73 1988 191 195
18. A. Saiki, T. Murano, and F. Watanabe Pitavastatin enhanced lipoprotein lipase expression in 3T3-L1 preadipocytes J Atheroscler Thromb 12 2005 163 168
19. K. Endo, Y. Miyashita, and A. Saiki Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia J Atheroscler Thromb 11 2004 341 347
20. M. Ohira, Y. Miyashita, and T. Murano Metformin promotes induction of lipoprotein lipase in skeletal muscle through activation of AMP activated protein kinase Metabolism 58 2009 1408 1414
21. D.G. Hardie, and S.A. Hawley AMP-activated protein kinase: the energy charge hypothesis revisited Bio Essays 23 2001 1112 1119
22. J.D. McGarry Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes Diabetes 51 2002 7 18
23. Y.P. Ching, S.P. Davies, and D.G. Hardie Analysis of the specificity of the AMP-activated protein kinase by site-directed mutagenesis of bacterially expressed 3-hydroxy 3-methylglutaryl-CoA reductase, using a single primer variant of the unique-site-elimination method Eur J Biochem 237 1996 800 808
24. S.P. Davies, N.R. Helps, and P.T. Cohen 5′-AMP inhibits dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein kinase. Studies using bacterially expressed human protein phosphatase-2C alpha and native bovine protein phosphatase-2AC FEBS Lett 377 1995 421 425 (Pubitemid 26027159)
25. S.R. Hamilton, J.B. O'Donnell Jr., and A. Hammet AMP-activated protein kinase: detection with recombinant AMPK {alpha}1 subunit Biochem Biophys Res Commun 293 2002 892 898 (Pubitemid 34694125)
26. S.H. Park, S.R. Gammon, and J.D. Knippers Phosphorylation-activity relationships of AMPK and acryl-CoA carboxylase in muscle J Appl Physiol 92 2002 2475 2482 (Pubitemid 34666373)
27. G. Zhou, R. Myers, and Y. Li Role of AMP-activated protein kinase in the mechanism of metformin action J Clin Invest 108 2001 1167 1174 (Pubitemid 32995375)
28. W.L. Isley, J.M. Miles, and B.W. Patterson The effect of high-dose simvastatin on triglyceride-rich lipoprotein metabolism in patients with type 2 diabetes mellitus J Lipid Res 47 2006 193 200 (Pubitemid 43107462)
29. J.G. Schneider, M. von Eynatten, and K.G. Parhofer Atorvastatin improves diabetic dyslipidemia and increase lipoprotein lipase activity in vivo Atherosclerosis 175 2004 325 331 (Pubitemid 38942913)
30. K. Schoonjans, J. Peinado-Onsurbe, and A.M. Lefebvre PPARalpha and PPARgamma activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene EMBO J 15 1996 5336 5348 (Pubitemid 26336216)
31. R. Kou, J. Sartoretto, and T. Michel Regulation of Rac 1 by simvastatin in endothelial cells: differential roles of AMP-activated protein kinase and calmodulin-dependent kinase kinase-beta J Biol Chem 284 2009 14734 14743
32. E.S. Buhl, N. Jessen, and O. Schmitz Chronic treatment with 5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside increases insulin-stimulated glucose uptake, signaling, and GLUT-4 content in rat muscle J Appl Physiol 88 2000 2219 2226
33. W. Sun, T.S. Lee, and M. Zhu Statins activate AMP-activated protein kinase in vitro and in vivo Circulation 114 2006 2655 2662 (Pubitemid 44967349)
34. H.C. Choi, P. Song, and Z. Xie Reactive nitrogen species is required for the activation of the AMP-activated protein kinase by statin in vivo J Biol Chem 283 2008 20186 20197
35. Y. Izumi, M. Shiota, and H. Kusakabe Pravastatin accelerates ischemia-induced angiogenesis through AMP-activated protein kinase Hypertens Res 32 2009 675 679
36. A.A. Gonzalez, R. Kumar, and J.D. Mulligan Effect of aging on cardiac and skeletal muscle AMPK activity: basal activity, allosteric activation, and response to in vivo hypoxemia in mice Am J Physiol Regul Integr Comp Physiol 287 2004 R1270 R1275
37. J.H. Moon, S.B. Kang, and J.S. Park Up-regulation of hepatic low-density lipoprotein receptor-related protein 1: a possible novel mechanism of antiatherogenic activity of hydroxymethylglutaryl-coenzyme A reductase inhibitor atorvastatin and hepatic LRP1 expression Metabolism 60 2011 930 940
38. A.L. Kater, M.C. Batista, and S.R. Ferreira Improved endothelial function with simvastatin but unchanged insulin sensitivity with simvastatin or ezetimibe Metabolism 59 2010 921 926
39. D.T. Furuya, A.C. Poletto, and R.R. Favaro Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice Metabolism 59 2010 395 399
40. J. Yang, S. Maika, and L. Craddock Chronic activation of AMP-activated protein kinase-alpha1 in liver leads to decreased adiposity in mice Biochem Biophys Res Commun 30 2008 248 253
41. Y. Zhang, J. Qiu, and X. Wang AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300 Arterioscler Thromb Vasc Biol 31 2011 2897 2908
42. X. Zhao, J.W. Zmijewski, and E. Lorne Activation of AMPK attenuates neutrophil proinflammatory activity and decreases the severity of acute lung injury Am J Physiol Lung Cell Mol Physiol 295 2008 L497 L504
43. C.F. Semenkovich, S.H. Chen, and M. Wims Lipoprotein lipase and hepatic lipase mRNA tissue specific expression, developmental regulation, and evolution J Lipid Res 30 1989 423 431 (Pubitemid 19082071)
44. D. An, T. Pulinilkunnil, and D. Qi The metabolic switch AMPK regulates cardiac heparin-releasable lipoprotein lipase Am J Physiol Endocrinol Metab 288 2005 246 253